MTZ - MasTec, Inc.

NYSE - NYSE Delayed Price. Currency in USD
63.50
+0.18 (+0.28%)
At close: 4:02PM EST

63.00 -0.50 (-0.79%)
After hours: 5:03PM EST

Stock chart is not supported by your current browser
Previous Close63.32
Open63.39
Bid63.51 x 2900
Ask63.52 x 3000
Day's Range63.13 - 63.71
52 Week Range40.51 - 73.71
Volume430,222
Avg. Volume934,412
Market Cap4.815B
Beta (5Y Monthly)1.35
PE Ratio (TTM)14.94
EPS (TTM)4.25
Earnings DateFeb 25, 2020 - Mar 01, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 02, 1982
1y Target Est76.54
  • 3 Monster Growth Stocks That Can Rip Higher in 2020
    TipRanks

    3 Monster Growth Stocks That Can Rip Higher in 2020

    Growth is the name of the game, of course; it’s the surest way for investors to get the returns they demand. And from a growth perspective, last year was a banner year. The three main indexes – the Dow Jones, the S&P 500, and NASDAQ – all finished the year with strong gains, ranging from 22% on the Dow to the NASDAQ’s 35%.We’re seeing that brisk growth continue this month, as the indexes are starting 2020 with gains between 2.8% and 4.6%. Even with some obvious headwinds brewing – the chaos of a U.S. presidential election year with a deeply polarized electorate –for now it looks like the markets are going to keep on trucking.We all know that past performance won’t guarantee future results. Still, the best place to start looking for tomorrow’s high-growth stocks is among yesterday’s winners. We’ve found three stocks that ended 2019 with hefty gains and put them side-by-side in the Stock Comparison tool from TipRanks. Here are the results. MasTec, Inc. (MTZ)We’ll start in the heavy industry sector, with a Florida-based leader in oil and gas, engineering, and construction. MasTec has been a fixture of the construction sector for over 20 years, and today is a $4.9 billion giant. Despite a slight slip in share prices during December, MTZ finished 2019 with an impressive overall appreciation of 57%.The impressive share gains are bolstered by a strong financial performance. MTZ last reported earnings at the beginning of November, and easily beat the EPS forecasts and the year-ago numbers. For revenue, MTZ reported $2.02 billion, which missed the forecast but was still up 2% year-over-year. The EPS number was better; at $1.73 it beat the estimate by 6% and the year-over-year number by 30%. Q3 was the fourth quarter in a row that MTZ beat the earnings forecast.Deutsche Bank analyst Chad Dillard is bullish on MTZ, seeing the company as well-positioned to continue its growth run. He writes, “Similar to 2Q, the earnings outperformance was rooted in oil and gas profitability, with segment margins ~530bps ahead of plan. Importantly, the company provided encouraging commentary on 2020, targeting low-double-digit sales growth… we remain constructive on shares, as the company is well-positioned to drive meaningful growth across its end-markets in ’20 and has continued a trend of outperforming expectations, not to be taken for granted in a challenging macro environment.”Dillard gives this stock a Buy rating with a price target of $77, suggesting strong continued gains, approaching 21% in the coming months. (To watch Dillard’s track record, click here)Overall, MTZ shares get a Strong Buy from the analyst consensus, based on 11 ratings, including no fewer than 10 Buys. Shares are selling for $63.75, and the average price target of $76.45 implies an upside potential of 20%. (See MasTec stock analysis on TipRanks) Biohaven Pharmaceutical Holding Company, Ltd. (BHVN)Our second pick today is a clinical-stage biotech. It’s common for biotech companies to operate at an earnings loss – they inhabit a niche with enormous overhead and exceedingly long lead times for new products. However, when new products do hit the market, new clinical trials start, or rumors spread of buyout possibilities, it’s not uncommon to see the shares spike. Biohaven has been the subject of such rumors since last spring, and despite high volatility, ended 2019 with a 48% gain.The company focuses its research mainly on drugs to treat migraines. This is a highly profitable space, but it does require a large salesforce right at the start. That need fed rumors that Biohaven was attracting buyers – rumors which turned out to be false. The company did, however, put out a secondary stock issue to raise capital, a move that raised over $322 million in new capital, despite temporarily depressing the share price. Gains so far in January have been modest, at nearly 3%.The company has excellent prospects moving forward, too, as its Rimegepant drug has recently shown positive Phase 3 trial results. Rimegepant is Biohaven’s lead product candidate, and a positive late-phase trial result will help bolster its approval application.Piper Sandler analyst Tyler Van Buren looks at Rimegepant through a broader lens, and sees general market reasons for a bullish stance on both the drug and the company. He notes that two competitors – Allergan and AbbVie – have received approval for a new drug in the same class as Rimegepant. The approval did not contain a warning about liver toxicity, and Van Buren sees this as a good sign for the drug class. He writes, “[T]his clearly bodes very well for the class as a whole and Biohaven's rimegepant, which had even cleaner safety and tolerability data.”Van Buren set a $100 price target on BHVN to back his Buy rating. That target indicates an impressive 79% upside potential. (To watch Van Buren’s track record, click here)Biohaven holds a Strong Buy consensus rating from the analysts, and it is unanimous. The rating is based on 7 Buys set in the last three months. The $78 average price target suggests an upside growth potential of 39% in the next 12 months. (See Biohaven stock analysis on TipRanks) Repay Holdings Corporation (RPAY)The final stock on today’s list presents an interesting case. Repay is holding company whose subsidiaries operate in the financial sector, primarily as fintech and payment processing providers. The company did not actually trade through the first half of 2019, as it was engaged in merger activity, joining with acquisition company Thunder Bridge.The transaction completed in early summer, and the company announced August 2 that RPAY shares had been reinstated on the NASDAQ index. Between the last week in July, when RPAY shares resumed active trading, and December 31, the stock showed a steady gain, finishing the year up 25%. RPAY has kept the pace in January, gaining another 9% so far this month.Repay reported Q3 earnings of 18 cents per share in November. That number was based on $19.4 million in gross profit, a 39% year-over-year gain. The company posted a total card payment volume of $2.6 billion, up 40% from the year before. Clearly, Repay’s merger activity and temporary halt in trading did not harm the company’s business.5-star analyst Mark Palmer, of BTIG, agrees, writing of the stock, “[S]hares of RPAY have appreciated by almost 41% in just over five months, we believe the stock still has ample upside, especially when considering the potential impact of a couple of acquisitions executed during 2H19 that provided the company with its own back-end payment processing platform and added the B2B payment vertical to its mix.”Palmer’s $20 price target on RPAY is in-line with his confidence in the stock – it implies an upside of 25% to the shares and backs up his Buy rating. (To watch Palmer’s track record, click here)RPAY also has a unanimous Strong Buy consensus rating, based on 5 Buys given in the past month. The average price target, $19, indicates room for a 19% upside from the current trading price of $15.97. (See Repay stock-price forecast on TipRanks)

  • MoneyShow

    Top Picks 2020- MasTec MTZ

    Last year, Richard Moroney selected Diodes (DIOD) as the Top Pick from his small-cap focused advisory service, Upside Stocks; the stock rose 69% and he still recommends the shares. For 2020, he turns to an engineering and construction company.

  • Why You Should Keep Sherwin-Williams (SHW) in Your Portfolio
    Zacks

    Why You Should Keep Sherwin-Williams (SHW) in Your Portfolio

    Sherwin-Williams (SHW) benefits from strong domestic demand, expansion actions and synergies of the Valspar acquisition.

  • Sherwin-Williams (SHW) Up 43% in a Year: What's Driving It?
    Zacks

    Sherwin-Williams (SHW) Up 43% in a Year: What's Driving It?

    Sherwin-Williams (SHW) gains from favorable demand in its domestic markets and growth through retail expansion.

  • An Intrinsic Calculation For MasTec, Inc. (NYSE:MTZ) Suggests It's 30% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For MasTec, Inc. (NYSE:MTZ) Suggests It's 30% Undervalued

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MasTec, Inc...

  • Looking for a Growth Stock? 3 Reasons Why MasTec (MTZ) is a Solid Choice
    Zacks

    Looking for a Growth Stock? 3 Reasons Why MasTec (MTZ) is a Solid Choice

    MasTec (MTZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • MasTec, Inc. (MTZ) vs. Hedge Fund Favorites in 2019
    Insider Monkey

    MasTec, Inc. (MTZ) vs. Hedge Fund Favorites in 2019

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • All You Need to Know About MasTec (MTZ) Rating Upgrade to Buy
    Zacks

    All You Need to Know About MasTec (MTZ) Rating Upgrade to Buy

    MasTec (MTZ) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • EMCOR (EME) Shares Up 46% YTD: Will the Rally Continue?
    Zacks

    EMCOR (EME) Shares Up 46% YTD: Will the Rally Continue?

    Strong demand across geographies and disciplined project execution bode well for EMCOR (EME). However, lower margin in the U.S. Mechanical Construction and Facilities Services segment poses concern.

  • Sherwin-Williams (SHW) Up 47% YTD: What's Driving the Rally?
    Zacks

    Sherwin-Williams (SHW) Up 47% YTD: What's Driving the Rally?

    Better-than-expected earnings performance and upbeat outlook for 2019 have contributed to the run-up in Sherwin-Williams' (SHW) shares.

  • What You Must Know About MasTec, Inc.'s (NYSE:MTZ) Beta Value
    Simply Wall St.

    What You Must Know About MasTec, Inc.'s (NYSE:MTZ) Beta Value

    Anyone researching MasTec, Inc. (NYSE:MTZ) might want to consider the historical volatility of the share price. Modern...

  • Hedge Funds Have Never Been This Bullish On MasTec, Inc. (MTZ)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On MasTec, Inc. (MTZ)

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • Here's Why You Should Hold Onto Sherwin-Williams for Now
    Zacks

    Here's Why You Should Hold Onto Sherwin-Williams for Now

    Sherwin-Williams (SHW) benefits from growth through retail expansion and synergies of the Valspar buyout.

  • Dycom's (DY) Shares Up More Than 8% on Q3 Earnings Beat
    Zacks

    Dycom's (DY) Shares Up More Than 8% on Q3 Earnings Beat

    Dycom Industries' (DY) third-quarter fiscal 2020 earnings and revenues surpass expectations owing to higher organic revenues.

  • Is MasTec (MTZ) Stock Outpacing Its Construction Peers This Year?
    Zacks

    Is MasTec (MTZ) Stock Outpacing Its Construction Peers This Year?

    Is (MTZ) Outperforming Other Construction Stocks This Year?

  • Zacks

    Starting a Short Week with New Highs

    Starting a Short Week with New Highs

  • Here is Why Growth Investors Should Buy MasTec (MTZ) Now
    Zacks

    Here is Why Growth Investors Should Buy MasTec (MTZ) Now

    MasTec (MTZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • PR Newswire

    MasTec Senior Management to Present at the Credit Suisse and UBS Investor Conferences in Palm Beach and New York

    CORAL GABLES, Fla., Nov. 22, 2019 /PRNewswire/ -- MasTec, Inc. (MTZ) today announced that its senior management will be in Palm Beach, Florida presenting at the Credit Suisse Industrials Conference on Wednesday, December 4th, at approximately 10:30 a.m. ET. Additionally, senior management will be in New York City presenting at the UBS Global Telecom Media and Technology Investor Conference on Monday, December 9th, at approximately 10:00 a.m. ET. Additionally, one-on-one meetings with institutional investors and MasTec's senior management are also being arranged as a part of the conferences.

  • PR Newswire

    MasTec Announces Details of Mas Family Financing Arrangements

    CORAL GABLES, Fla., Nov. 19, 2019 /PRNewswire/ -- MasTec, Inc. (MTZ) today announced that Jorge Mas, Chairman, and Jose Mas, Chief Executive Officer (together with certain family partnerships and trusts, the "Mas Brothers"), have entered into financing arrangements (the "Financings") involving prepaid variable forward contracts  with respect to  MasTec common stock, as described in more detail in various filings with the Securities and Exchange Commission ("SEC") on or about the date of this press release. The Mas Brothers remain committed to being long-term shareholders of MasTec and currently have no intent to sell or enter into additional financings involving their MasTec shares. The Financings provide the Mas Brothers the ability to receive cash now, while retaining full ownership and voting rights during the three-year initial term.

  • Dycom (DY) to Report Q3 Earnings: What's in the Offing?
    Zacks

    Dycom (DY) to Report Q3 Earnings: What's in the Offing?

    Delayed deployments from a major cable customer are likely to get reflected in Dycom Industries' (DY) fiscal Q3 results.

  • Sherwin-Williams (SHW) Up 38% in 6 Months: What's Driving It?
    Zacks

    Sherwin-Williams (SHW) Up 38% in 6 Months: What's Driving It?

    Better-than-expected Q3 earnings performance and upbeat prospects have contributed to the rally in Sherwin-Williams' (SHW) shares.

  • Here's Why MasTec (MTZ) is a Great Momentum Stock to Buy
    Zacks

    Here's Why MasTec (MTZ) is a Great Momentum Stock to Buy

    Does MasTec (MTZ) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Zacks

    Dow All Alone at New Highs

    Dow All Alone at New Highs

  • This Insider Has Just Sold Shares In MasTec, Inc. (NYSE:MTZ)
    Simply Wall St.

    This Insider Has Just Sold Shares In MasTec, Inc. (NYSE:MTZ)

    We'd be surprised if MasTec, Inc. (NYSE:MTZ) shareholders haven't noticed that the Independent Director, Robert Dwyer...

  • Is MasTec (MTZ) a Solid Growth Stock? 3 Reasons to Think " Yes "
    Zacks

    Is MasTec (MTZ) a Solid Growth Stock? 3 Reasons to Think " Yes "

    MasTec (MTZ) could produce exceptional returns because of its solid growth attributes.